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OBJECTIVES:Leptinandadiponectin(APN)areadipokinesproducedbyadipocytesthatparticipateinthemodulationofimmune
and inﬂammatory responses. In Crohn’s disease (CD), fat wrapping surrounding the inﬂamed intestine produces high levels of
leptin and APN. In inﬂammatory bowel disease (IBD), apoptosis resistance of lamina propria T lymphocytes (LPL-T) is one of the
mechanisms that maintains chronic inﬂammation. We addressed the mechanism by which leptin and APN regulate inﬂammation
and apoptosis in IBD.
METHODS: Immune cell inﬁltration, several factors expressed by adipose tissue (AT), and spontaneous release of cytokines by
adipocytes were measured. The presence of APN and leptin in intestinal mucosa was detected and their effect on LPL-T
apoptosis, signal transducer and activator of transcription 3 (STAT3), Suppressor of Cytokine Signaling 3 (SOCS3), Bcl-2 and
Bcl-xL expression, and cytokine production was studied. In addition, the effects of globular and high-molecular-weight (HMW)
APN on LPL-T cytokine production and apoptosis were studied.
RESULTS: Higher levels of several chemokines, cytokines, and growth factors were present in AT near active than near inactive
disease. A signiﬁcantly higher amount of inﬂammatory inﬁltrate was present in AT near active CD than near ulcerative colitis,
controls, and near the inactive area of CD. There were no changes in the ratios of APN molecular weight in control and IBD
adipocyte products. Leptin and APN inhibited anti-CD3-stimulated-LPL-T apoptosis and potentiated STAT3 phosphorylation,
Bcl-2,andBcl-xLexpressioninIBDandcontrolmucosa.However,SOCS3expressionwassuppressedonlyinIBD.Bothglobular
and HMW APN have similar effects on LPL-T cytokine production and apoptosis. Leptin and APN enhanced interleukin (IL)-10
production byanti-CD3-stimulated LPL-TinIBD only. APN, but notleptin, increased anti-CD3-inducedIL-6 levels inLPL-T only in
IBD patients. IL-10 exerts its anti-inﬂammatory activity in the presence of SOCS3 suppression by leptin or APN.
CONCLUSION: Leptin and APN maintain the inhibition of anti-CD3-stimulated LPL-T apoptosis by enhancing Bcl-2 and Bcl-xL
overexpression and promoting STAT3 phosphorylation while suppressing SOCS3.
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INTRODUCTION
Resistance of lamina propria T lymphocytes (LPL-T) to
apoptosis is one of the key mechanisms that maintains
chronic inﬂammation in inﬂammatory bowel disease (IBD).
1
LPL-T from IBD patients have stronger in vitro proliferative
responses to T-cell receptor/CD3 stimulation than those from
normal mucosa,
2 and they spontaneously proliferate in
subjects with Crohn’s disease (CD).
3 These studies suggest
that LPL-T in the mucosa of IBD patients, unlike the LPL-T of
normalmucosa, reactmorestronglyto exogenousantigensto
which the mucosal T cells are constantly exposed. However,
the mechanism of this LPL-T longevity and over-reactivity in
IBD is not well established.
Several lines of evidence suggest that cytokines have a
central role in the observed abnormal LPL-T function in IBD.
4
However, the sourceof thecytokines responsible forthe over-
reactivity and longevity of LPL-T is relatively unknown.
Several recent clinical and experimental observations point
to the mesenteric adipocytes. For example, there is evidence
that obesity is associated with a heightened inﬂammatory
response in CD patients.
5 Furthermore, intestinal luminal
leptin, a cytokine produced by adipocytes, is increased in IBD
and can upregulate nuclear factor kappa B expression in
colonic epithelial cells.
6 CD patients also typically display
alterations of mesenteric fat depots, or ‘creeping fat’,
suggesting that the local adipose tissue (AT) and adipokines
may be involved in the pathogenesis of IBD.
7 These patients
present with a selective enlargement of fat depots around the
diseasedlymphnodesandintestine,withanestimated450%
of the intestinal surface being covered by AT.
8 A recent study
demonstrated that fat wrapping is present in 100% of the
patients with CD undergoing ileal resection and correlates
signiﬁcantly with the degree of acute and chronic inﬂamma-
tion, and particularly with the extent of transmural inﬂamma-
tion in the form of lymphoid aggregates.
9 This peri-intestinal
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overexpression of tumor necrosis factor-alpha and leptin.
10
Levels of adiponectin (APN), another cytokine produced by
adipocytes,arealsoincreasedinthefatwrappingsurrounding
Crohn’s lesions.
11 Therefore, it is likely that a vicious cycle
between AT and immune cells is the critical factor maintaining
the sustained and intense intestinal inﬂammation required for
tissue injury in patients with IBD. For example, leptin directly
regulates production of several cytokines, particularly
from T cells.
12 In fact, leptin increases interleukin (IL)-2 and
IFNg production, while decreasing IL-4 levels.
12 Therefore,
leptin may have an important role in the regulation of the
T-helper (Th)1/Th2 balance, which appears to be critical
in the pathogenesis of IBD. Furthermore, APN modulates the
inﬂammatory process and thus can also contribute to
regulation of chronic intestinal inﬂammation in IBD. However,
unlike leptin, the role of APN in inﬂammation is not
straightforward and several studies report conﬂicting results,
possibly because of its multi-molecular weights. Several
investigators have reported that APN has anti-inﬂammatory
effects, including inhibition of tumor necrosis factor-alpha
production and activity, inhibition of nuclear factor kappa B
activation, and induction of anti-inﬂammatory cytokines,
13
while we
14 and others
15,16 have shown that APN also exerts
pro-inﬂammatory effects. In particular, a pro-inﬂammatory
role for APN has been suggested in the context of arthritis by
the demonstration that APN selectively induces production of
IL-6 and matrix metalloproteinase-1 from synovial ﬁbro-
blasts.
15 Furthermore, in the human colonic epithelial cell line
HT-29, APN stimulates proliferation and production of pro-
inﬂammatory cytokines.
16
How do adipokines promote LPL-T over-reactivity and
longevity in IBD? Signal transducer and activator of transcrip-
tion 3 (STAT3) and Suppressor of Cytokine Signaling 3
(SOCS3) are not only involved in intestinal inﬂammation,
17
but they are also modulated by adipokines.
18 It has been
shown that high levels of phosphorylated STAT3, the active
form, are presentin bothCD and ulcerativecolitis (UC), but not
in healthy intestine.
17 Cytokines such as IL-6, IFN-g, and leptin
activate STAT3,
19 while APN suppresses STAT3 activation.
20
However, IL-10 requires STAT3 activation for its anti-inﬂam-
matoryproperties,
21indicatingthatSTAT3canbeapartofboth
pro- and anti-inﬂammatory pathways. Interestingly, STAT3
mediates apoptosis resistance in chronic intestinal inﬂamma-
tion
22 by binding to the promoter region of Bcl-xL and thereby
enhancing transcription of this protein.
23 In this report, we
sought to elucidate the mechanism of LPL-T longevity and
over-reactivity in IBD and to determinewhether leptin and APN
exert pro-inﬂammatory and anti-apoptotic activities on the
intestinal LPL-T of patients with IBD. We demonstrate that
leptin and APN maintain the pro-inﬂammatory state and
increase apoptosis resistance in the LPL-T of IBD patients,
possibly by STAT3 activation and SOCS3 suppression.
METHODS
Patients, sample collection, and chemokine, cytokine,
and growth factor expression by AT. Patients with UC
and CD were 25–65 years of age (n¼12 of each group, six
females and six males) and their average body mass index
was 19.8kg/m
2. The diagnosis of IBD was based on
standard clinical, endoscopic, and histological criteria. All
patients had symptomatic active IBD that required surgical
treatment. IBD patients were on corticosteroids and/or
immunosuppressant medications. Indication for surgery
varied from adenocarcinomas for controls to strictures or
ﬁstula for CD, and hemicolitis or pancolitis for UC. The use of
medication and indication for surgery were recorded. A
summary of patient characteristics, medication use, and
indications for surgery is shown in Table 1.
Intestinal mucosa was obtained from the macroscopically
involved area and active inﬂammation was conﬁrmed by
histological examination of the involved area. From all IBD
subjects, mucosal samples from the macroscopically unin-
volved area at the margin of the resected bowel were also
collected, and histological examination of these segments
conﬁrmed the lack of histological evidence of active inﬂam-
mation. This study was approved by the institutional review
board for safety of human subjects at the University of Illinois
at Chicago, Rush University and the University of South
Carolina.
Inaddition tomucosal samples, ATwascollected. For more
details, see Supplementary Materials online.
LPL-T and adipocyte isolation. For LPL-T and adipocyte
isolation, see Supplementary Materials online.
Adipokine, cytokine release, and APN fractionation.
Freshly isolated adipocytes were collected. Cell number was
normalized by the weight of AT at 1g/ml/well. Adipocytes
were incubated in 24-well plates overnight. To measure IL-6,
leptin, and APN production by adipocytes, 4mg/ml of
adipocyte supernatant, taken from each sample, and
ELISA kits for IL-6 (BD Bioscience, San Jose, CA), leptin,
and APN (eBioscience, San Diego, CA) were used.
To measure IL-6 and IL-10 production by LPL-T, ﬂat-
bottomed 96-well plates (Becton-Dickinson, San Jose, CA)
were pre-coated with anti-CD3 monoclonal antibody
(BD Bioscience) (5mg/ml) for 2h at 371C. The isolated LPL-T
(1 10
5) were added to wells in the plate in 100mlo fR P M I
Table 1 Demographic details of controls and IBD patients
Controls
(n¼12)
CD
(n¼12)
UC
(n¼12)
Median age±s.d. (years) 49.6 34.9 37.8
Gender (female/male) 6/6 6/6 6/6
Use of medications (female/male)
Corticosteroids alone 0/0 2/0 0/0
Immunosuppressant alone 0/0 0/2 1/0
Combined use of corticosteroids
and immunosuppressant
0/0 4/4 4/6
Indication for surgery (female/male)
Adenocarcinoma 6/6 0/0 0/0
Stricture 0/0 4/4 0/0
Fistula 0/0 2/2 0/0
Pancolitis 0/0 0/0 4/4
Hemicolitis 0/0 0/0 2/2
CD, Crohn’s disease; IBD, inﬂammatory bowel disease; UC, ulcerative colitis.
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penicillin, and 100mg/ml streptomycin. Anti-CD3-stimulated
cells were incubated overnight in the presence or absence of
20ng/ml of human recombinant leptin or 2mg/ml of human
recombinant globular APN (Peprotech, Rocky Hill, NJ). LPL-T
were collected for further study and their supernatant
(2mg/ml)was used todetect IL-6and IL-10 levelsusing ELISA
kits from BD Bioscience. The distribution of APN multimeric
forms, from mesenteric AT in IBD, was examined in
adipocyte-derived products (ADPs) after fractionation as
previously described
14 using the Hi-Load Superdex Column
(GE Healthcare, Uppsala, Sweden) and ELISA technique. The
effect of HMW versus LMW and MMW of APN on LPL-T
cytokine production and apoptosis was studied in addition
to the effect of IL-10 on IL-6 production by LPL-T (see
Supplementary Materials and Results online).
APN, leptin, and SOCS3 expression in control and IBD
mucosa. For APN, leptin, and SOCS3 expression in control
and IBD mucosa, see Supplementary Materials online.
SOCS3 expression by LPL-T in control and IBD mucosa.
To detect SOCS3 expression by LPL-T of control and IBD
patients, freshly isolated LPL-T (1 10
5) were incubated in
5mg/ml anti-CD3-pre-coated 96-well plates overnight. Leptin
(20ng/ml) or APN (2mg/ml) was added and LPL-T were
incubated for 1h at 371C and 5% CO2. Cells were collected.
A proportion of the cells (5 10
4) were ﬁxed by 4%
formaldehyde for later use to detect STAT3 and p-STAT3,
and the remaining cells were frozen. Quantitative RT-PCR
for SOCS3 was performed as previously described
4 and
normalized by calibrating against the expression of 18S RNA.
STAT3 and p-STAT3 expression by LPL-T. LPL-T (5 10
4),
treated with anti-CD3 in the presence or absence of leptin or
APN, were ﬁxed to detect STAT3 and p-STAT3 expression
using the Raybio ELISA kit (Raybiotech, Norcross, GA)
following the manufacturer’s instructions.
Evaluation of apoptosis and cell viability. For apoptosis
and cell viability detection in LPL-T, see Supplementary
Materials online.
Protein extracts and western blot analysis. For protein
extracts and western blot analysis, see Supplementary
Materials online.
Hematoxylin and eosin staining of AT. To grade immune
cell inﬁltration in the AT of control and IBD patients, the tissue
was ﬁxed in 10% buffered formalin overnight and parafﬁn
embedded. Sections were stained with hematoxylin and eosin.
The scores for AT immune cell inﬁltration are as follows:
0¼none, 1¼mild, 2¼moderate, 3¼severe immune cell
inﬁltration. Scoring was performed in a blinded manner by a
pathologist (RJC).
Immunohistochemistry of APN and leptin in IBD and
control mucosa. To detect local APN and leptin presence
in mucosa, tissue sections (5mm) were stained for APN
or leptin using goat anti-human APN (10mg/ml) or leptin
(1mg/ml) antibody (R&D Systems, Minneapolis, MN) and the
reaction was developed using diaminobenzidine. Two sets of
controls were performed to ensure the speciﬁcity of the
staining: (1) sections were stained with goat immunoglobulin
G; (2) antibodies were pre-incubated with the respective
recombinant proteins (10mg/ml) for 1h at room temperature
before performing the staining procedure.
Statistical analysis. Differences in parameters were
examined using factorial ANOVA and Student’s T-test by
the XLStat software (Addinsoft, Brooklyn, NY, USA).
RESULTS
Chemokine and cytokine expression by AT of CD. To
evaluate the extent of AT inﬂammation in CD, levels of
chemokines, cytokines, and growth factors were compared in
the AT obtained near the active and inactive areas of the
ileum from 12 CD patients (Table 2).
Despite high expression of pro-inﬂammatory cytokines
such as IL-17 and IL-23, there is higher expression of IL-10
in active CD, indicating that creeping fat in an active CD may
modulate the inﬂammatory environment or may be an
extension of the mucosal inﬂammatory milieu.
Adipokine and cytokine release from mesenteric AT in
IBD. To investigate the production of AT-derived adipokines
and cytokines in CD and UC, adipocytes were isolated,
cultured overnight, and release of APN, leptin, and IL-6 was
measured in the supernatant. As shown in Figure 1a,
signiﬁcantly higher levels of APN and IL-6 were released
from adipocytes obtained from active areas of both UC and
CD patients compared with adipocytes from inactive sites
and controls. A similar ﬁnding was observed for leptin in UC
patients, whereas leptin release was signiﬁcantly increased
in CD patients compared with controls irrespective of the site
of origin of adipocytes. Furthermore, fractionations of
APN obtained from ADP were compared to evaluate the
relative presence of high- (HMW) vs. moderate- (MMW) and
low-molecular-weight (LMW) complexes. As indicated in
Supplementary Table 1, the percentage distribution of APN
was comparable in each of the samples analyzed.
Inﬂammatory inﬁltrate in AT in IBD. To evaluate adipocyte
size and the presence of inﬂammatory inﬁltrate, histological
analysis of AT obtained from CD, UC, and control subjects
was performed. Adipocyte size was comparable in each group
of patients and site of origin of AT (Figure 1b). A signiﬁcantly
higher inﬂammatory inﬁltrate was present in AT near active
CD lesions compared with AT near the inactive segment of the
intestine in CD (Figure 1b and c). In contrast, the inﬂammatory
inﬁltrate of AT from UC patients was comparable to that of
control subjects irrespective of the site of origin.
Adipokine expression and presence in control and IBD
mucosa. To evaluate whether APN and leptin are
expressed in the intestinal mucosa, PCR, quantitative RT-
PCR, and immunohistochemical studies were performed.
As shown in Figure 2a, mRNA for both APN and leptin was
Adipokines and IBD
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APN mRNA levels were observed in control compared with
IBD patients, whereas leptin expression was variable among
the groups (Figure 2b). Immunohistochemistry analysis
revealed that, at the protein levels, APN was not detectable
in control mucosa, whereas leptin was present in the lamina
propria and in epithelial cells of control subjects. Both APN
and leptin were detectable in mucosa obtained from active
CD and UC, with high immune reactivity in the lamina propria
(Figure 3). APN and leptin in inactive IBD mucosa have
similar patterns of expression and presence as seen in
control mucosa (data not shown).
Effects of leptin and APN on LPL-T apoptosis. As
previously demonstrated,
1,24 high rates of apoptosis were
observed in unstimulated LPL-T obtained from control
subjects compared with either CD or UC patients. The rate
of LPL-T cell apoptosis in controls was 2.5-fold more than
that in IBD patients (Figure 4). Stimulation of LPL-T with anti-
CD3 signiﬁcantly increased LPL-T apoptosis in cells obtained
from both control subjects and IBD patients. Addition of
either leptin or APN signiﬁcantly reduced the apoptosis
rates in anti-CD3-stimulated LPL-T, with comparable effects
observed in cells obtained from control and IBD subjects.
When mucosal-derived products (MDPs) were evaluated for
APN and leptin content, a signiﬁcant release of APN and
leptin from mucosal tissue was observed in cultures of a
larger sample (1cm
2) as compared with 2mm
2 sample size.
In addition, LPL-T apoptosis was evaluated in different MDP-
level treatments (Table 3). Furthermore, STAT3 inhibitor ‘WP
1066’ rescued the LPL-T of control and IBD from undergoing
apoptosis, suggesting that STAT3 has a direct effect on LPL-
T viability (Figure 4). As HMW APN activates nuclear factor
kappa B
25 and induces IL-6 in human monocytes,
26 we
studied the effect of HMW on LPL-T apoptosis and IL-6
production in IBD. We found that HMW APN had a similar
effect as the recombinant globular APN (Supplementary
Table 1). In contrast, MMW and LMW did not have any effect
on LPL-T apoptosis (data not shown).
Effects of leptin, APN, and IL-10 on cytokine release by
LPL-T. To characterize the effects of leptin, APN, and IL-10
on cytokine production by LPL-T, levels of IL-6 and IL-10
were measured. For more details, see Supplementary Data
online.
Cell survival and anti-apoptotic protein expression by
LPL-T. Changes in cytokine production by LPL-T correlate
closely with the cell survival effects of the different treatments.
Therefore, we studied LPL-T cell viability in culture using
the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
assay. We found that leptin and APN enhanced the survival
rates of anti-CD3-treated LPL-T to levels similar to that
observed prior to anti-CD3 treatment in all groups,
suggesting that both leptin and APN exert anti-apoptotic
activities in individuals with IBD (Figure 5a). In order to study
the mechanism that promotes LPL-T apoptosis resistance,
the expression of anti-apoptotic proteins Bcl-xL and Bcl-2
was measured. Addition of leptin or APN to anti-CD3-
stimulated LPL-T enhanced Bcl-xL and Bcl-2 expression in
both control and IBD (Figures 5b and c).
Effects of leptin and APN on STAT3, p-STAT3, and SOCS3
expression by LPL-T. Activation of STAT3 and expression
of SOCS3 were evaluated in unstimulated and anti-CD3-
stimulated LPL-T in the presence or absence of leptin or
APN. As shown in Figure 6a, comparable levels of p-STAT3
were observed in unstimulated LPL-T obtained from control,
CD, and UC patients. Addition of APN signiﬁcantly increased
p-STAT3 in cells from UC and CD patients but had no effect
Table 2 Chemokine, cytokine, and growth factor expression by adipose tissue
in CD
Inactive CD Active CD
(average±STE)
a (average±STE)
b
Chemokines
Eotaxin-2 (CCL24) 0.77±0.77 23.63±2.55
Eotaxin-3 (CCL26) 1.07±0.58 76.57±6.15
Fractalkine (CX3CL1) 1.47±0.35 62.89±6.03
GCP-2 (CXCL6) 0.00±0.00 39.2±2.47
I-309 (CCL1) 0.17±0.09 29.53±2.60
MCP-1 (CCL2) 0.00±0.00 27.38±3.21
MCP-2 (CCL8) 0.00±0.00 18.37±2.23
MCP-4 (CCL13) 0.00±0.00 28.17±1.95
MDC (CCL22) 0.00±0.00 52.67±5.20
MIG (CXCL9) 0.00±0.00 53.9±3.98
MIP-1g (CCL9) 0.00±0.00 58.8±3.77
MIP-3a (CCL23) 0.00±0.00 66.23±6.99
NAP-2 (CXCL7) 1.40±1.40 107.91±6.35
PARC (CCL18) 0.00±0.00 36.9±7.31
Cytokines
IL-1a 0.18±0.10 62.39±4.59
IL-1b 0.61±0.31 69.48±2.90
IL-1ra 0.95±0.12 81.84±2.55
IL-2 0.63±0.35 90.09±4.32
IL-3 2.72±0.22 104.23±3.24
IL-4 0.40±0.40 61.69±14.02
IL-5 0.03±0.03 33.80±4.27
IL-6 0.40±0.40 190.21±16.57
IL-7 0.13±0.13 27.02±6.38
IL-10 2.11±0.21 12.43±1.20
IL-13 0.57±0.35 7.5±0.45
IL-15 0.63±0.38 27.27±2.04
IL-16 0.07±0.07 22.67±1.31
IL-17 0.84±0.07 65.17±7.20
IFN-g 0.00±0.00 6.66±0.78
TNF-a 0.00±0.00 20.17±1.16
Growth factors
Angiogenin 2.27±0.49 54.61±8.38
BMP-6 0.40±0.40 30.43±6.93
FGF-6 2.55±0.84 74.67±5.52
FGF-7 0.00±0.00 39.63±3.58
Flt-3 ligand 0.57±0.43 40.93±5.01
GM-CSF 0.48±0.37 50.62±13.59
MCS-F 0.00±0.00 43.57±4.23
TGF-b 0.00±0.00 2.10±0.09
NT-3 0.00±0.00 39.28±2.24
BMP, bone morphogenetic protein; CD, Crohn’s disease; FGF, ﬁbroblast
growth factor; GCP-2, granulocyte chemotactic protein-2; IFN, interferon; IL,
interleukin; MCP, monocyte chemotactic protein; MCS-F, macrophage colony
stimulating factor; MIP, macrophage inﬂammatory protein; MIG, monokine
induced by gamma interferon; NAP-2, neutrophil-activating protein-2; NT-3,
neurotrophin-3; PARC, pulmonary and activation-regulated chemokine; STE,
standard error; TGF, tumor growth factor; TNF, tumor necrosis factor.
Note: Chemokine, cytokine, and growth factor expression by mesenteric
adipose tissue was obtained near active and inactive CD.
aData represent the
average of OD readings of spot density.
bPo0.001 vs. levels in inactive CD
(n¼12).
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Clinical and Translational Gastroenterologyon cells from control subjects, whereas leptin did not
signiﬁcantly alter p-STAT3 levels in unstimulated cells from
any of the groups. In contrast, both leptin and APN
signiﬁcantly increased p-STAT3 levels in anti-CD3-
stimulated cells from control, UC, and CD patients, with a
signiﬁcantly stronger effect observed in cells from IBD
patients, particularly CD, compared with control subjects.
As shown in Figure 6b, expression of SOCS3 in LPL-T from
control subjects was not signiﬁcantly altered by any of the
culture conditions. In contrast, both leptin and APN signiﬁ-
cantly reduced SOCS3 expression in anti-CD3-stimulated
LPL-T from UC and CD patients, with a more marked effect
in cells from CD patients. In this latter group, APN also
signiﬁcantly reduced SOCS3 expression in unstimulated
LPL-T.
Thus, in agreement with the data on cytokine production,
LPL-T from IBD patients appeared to be more susceptible to
theeffects ofleptin andAPN onSTAT3 activationandSOCS3
expression, compared with cells obtained from control
subjects.
DISCUSSION
Creeping fat that surrounds CD lesions is one of the hallmarks
of CD. The extent of the creeping fat typically correlates with
the severity of intestinal inﬂammation and tissue injury. This
clinical observation suggests an important role for AT in the
intestinal inﬂammatory process in CD. Thus, we ﬁrst sought to
study the chemokine and cytokine expression in AT of active
and inactive CD. We found that hypertrophied, inﬂamed, AT
near active CD expresses many chemokines, Th1, and Th2
cytokines, which places the already inﬂamed mucosa into an
additional microenvironment that may potentiate either more
inﬂammatory cascades, by releasing inﬂammatory chemo-
kines and cytokines, or produce anti-inﬂammatory factors that
counteract the inﬂammatory condition in the mucosa. It is
noteworthy that IL-10 expression is increased in the AT of
active CD possibly because of the corticosteroid use of most
of the patients.
27 In addition, the expression of IL-17 is
increasedintheactivephaseofCD,suggestingthattheTh-17
cells inﬁltrate in the AT. Also, the increased expression of
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Figure 1 Adipose tissue release of adiponectin (APN), leptin, and interleukin (IL)-6, and cell inﬁltration. (a) Adipocytes, obtained from the mesenteric adipose tissue (AT)
adjacent to the active and inactive areas of inﬂammatory bowel disease (IBD) and control mucosa, were isolated and incubated at 371C and 5% CO2 overnight. Active and
inactive mucosa were obtained from the same patient and conﬁrmed histologically (n¼12). Adiponectin, leptin, and IL-6 levels were measured in the supernatant. *Po0.04
vs.levelsininactiveareasofIBD.(b)RepresentativehematoxylinandeosinstainingofAT.(c)ImmunecellinﬁltrationscoreintheATofcontrolandIBD.*Po0.05vs.levelsin
the inactive area of Crohn’s disease (CD). UC, ulcerative colitis.
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Clinical and Translational GastroenterologyIL-23 in active disease further supports that IL-23 either via
IL-17 or directly is linked to the presence of Th-17 cells in the
creeping fat of CD. The latter interpretation is suggested
by the ﬁndings of IL-23 as a T-cell-independent inducer of
mucosal inﬂammation.
28
We then measured the spontaneous production of leptin,
APN, and IL-6 by adipocytes obtained near active IBD and
found that these cytokines are produced at higher levels than
those produced by adipocytes from the inactive segments of
the intestine from IBD patients. Despite higher levels of
systemic leptin and APN in healthy women than in healthy
men,
29 we found insigniﬁcant differences in local adipocyte
production of leptin and APN in healthy and IBD women vs.
male patients (data not shown). This ﬁnding suggests that the
high levels of local leptin and APN in active IBD are gender
independent. However, our ﬁndings should be conﬁrmed in a
larger sample.
Finally, we assessed immune cell inﬁltration in AT and found
that it is increased signiﬁcantly near active CD, suggesting that
ADP increases the production of chemokines
30 that attract
more immune cells and therefore participate in the inﬂamma-
tory milieu near CD. However, immune cell inﬁltration was not
alteredinATnearactiveUC.Thisobservationcanbeexplained
bytheabsenceoffatwrappinginUClesionsandthesuperﬁcial
nature of mucosal inﬂammation in UC. In contrast, the
inﬂammatory process in CD is a transmural one involving the
entirethickness ofthe intestinal wall. This wouldleadtoa close
interaction of mesenteric AT with the intestinal inﬁltrated
immune cells and exposure of the surrounding AT to the
immune cell-derived chemokines and growth factors, resulting
in attraction of more immune cells to the AT and promotion of
adipogenesis
31 and angiogenesis.
Leptin and APN are expressed and present in IBD mucosa.
In contrast to a previous report showing that leptin was absent
in normal mucosa,
6 we found that leptin was present in
epithelial cells and the lamina propria layer in both control and
IBD patients. Furthermore, leptin and APN were produced
by mucosal IBD. Our ﬁnding is supported by a prior study
reporting that leptin, secreted by gastric epithelium, can reach
the intestine in an active form and has the potential to act on
luminal targets.
32 However, being more prevalent in IBD
mucosa than leptin, APN may have a key role in modulating
the local inﬂammatory environment.
In the present study, we conﬁrmed our prior ﬁndings in a
dextran sulfate sodium (DSS) animal model of colitis and
showed that APN staining distribution was found in active
IBD.
14 Whether leptin or APN is produced by epithelial cells or
taken up by the epithelial cells from the luminal intestinal
content remains to be determined.
One of the mechanisms of dysregulated mucosal immune
response and ‘over-reactive’ mucosal immune cells in IBD
is the reduction of LPL-T apoptosis rate.
33 Apoptosis helps
regulate mucosal lymphocyte population size, terminates the
immune response at sites of antigen exposure, and prevents
the activation and clonal expansion of potentially self-reactive
lymphocytes. We and others have shown that mucosal T cells
in IBD are resistant to apoptosis.
24,34 In this report, we show
thatleptin andAPN diminishedtheapoptosisrateinanti-CD3-
stimulated LPL-T of control and IBD patients. Leptin inhibition
of LPL-T apoptosis is most likely due to the upregulation of an
anti-apoptotic gene such as Bcl-xL.
35 As local levels of leptin
and APN are elevated in IBD as compared with controls
6,11
and as demonstrated in Table 3, the possible effect of leptin
and APN on the apoptosis resistance of LPL-T in IBD is
greater than that in control LPL-T. Our data are supported by
published reports indicating that leptin exerts anti-apoptotic
activities in stress-induced apoptosis in T lymphocytes.
35
Similarly, APN reduced the apoptosis rate in anti-CD3-
activated LPL-T in both control and IBD samples. This ﬁnding
is in contrast with the pro-apoptotic and anti-inﬂammatory
activities of APN on endothelial cells.
36 However, APN can
also mediate anti-apoptotic activity in pancreatic beta cells,
37
suggesting that the cell target and the type of inﬂammatory
microenvironment might have a critical role in determining the
roleofAPNasapro-vs.anti-apoptoticmolecule.HowdoLPL-
T evade apoptosis? STAT3 has a role in apoptosis resis-
tance
22andisactivatedintheLPL-TofIBDpatients.
17Hence,
we found that inhibiting STAT3 activation increased LPL-T
apoptosis, indicating that STAT3 has a crucial role in LPL-T
apoptosis resistance that leads to chronic inﬂammation in
IBD. A possible mechanism whereby STAT3 exerts its anti-
apoptotic activity is through overexpression of anti-apoptotic
proteins such as Bcl-2
38 and Bcl-xL.
39 Hence, we show that
Bcl-2 and Bcl-xL expression is enhanced in anti-CD3-
stimulated LPL-T that were treated with leptin or APN in
control with remarkable expression in IBD.
Neither leptin nor APN increases the IL-6 production in anti-
CD3-stimulatedLPL-Tofcontrolmucosa.Inaddition,leptindid
not enhance the IL-6 production of anti-CD3-stimulated LPL-T
of IBD patients, despite IL-6 expression by LPL-T (data not
shown),butitspresence wassufﬁcienttoactivatetheLPL-Tto
produceIL-10thatmaycounteracttheinﬂammatoryfunctionof
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Figure 2 (a) Representative messenger (m)RNA expression for adiponectin
(APN), leptin, and GAPDH in the colonic mucosa of control (C) and active
inﬂammatory bowel disease (IBD). (b) Quantitative reverse transcriptase-
polymerase chain reaction for APN and leptin in the control adipose and colonic
tissues obtained from active IBD mucosa. *Po0.05 vs. control mucosa (n¼12 per
group). CD, Crohn’s disease; GADPH, glyceraldehyde-3-phosphate dehydro-
genase; UC, ulcerative colitis.
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Clinical and Translational GastroenterologyIL-6. On the other hand, APN augmented the production of
IL-6 and IL-10 by anti-CD3-stimulated LPL-T in IBD compared
with control mucosa, suggesting that activated LPL-T of IBD
patients are susceptible to APN activation. The proinﬂamma-
tory effect of APN on IL-6 production has also been observed
in mouse cardiac ﬁbroblasts.
18 However, it is important to note
that a compensatory anti-inﬂammatory activity of IL-10 may
counteract APN and hence block its bioactivity.
In our study, treatment of anti-CD3 activated STAT3 in the
LPL-T of control and IBD mucosa. However, leptin-sensitized
anti-CD3 stimulated LPL-T that led to a signiﬁcant
overexpression of p-STAT3 in the LPL-T of control mucosa.
In addition, a signiﬁcant increase in p-STAT3 expression
is present in anti-CD3-stimulated LPL-T of UC, suggesting
that local leptin is active and could bind to its receptor on
LPL-T.
The effect of APN on the transcription factor STAT3 is not
well established and several studies have demonstrated
conﬂicting results. For example, APN inhibits p-STAT3
expression in hepatocellular and prostate cancer cell lines
20
and thus APN appears to act as a pro-apoptotic molecule.
In contrast, we and others found that APN served as a pro-
inﬂammatory cytokine
14,40 and induced STAT3 activation in
cardiac ﬁbroblasts.
18 In the present study, we found that
APNactivatedSTAT3 inthe LPL-TofintestinalmucosalT cells
in IBD patients independent of anti-CD3 stimulation. APN
activates STAT3 in both unstimulated and anti-CD3-stimulated
LPL-T cells from IBD patients. Our ﬁnding suggests that the
LPL-TofIBDpatientsaresensitizedtoAPNintheabsenceofa
stimulus thatleadstoSTAT3activation.IncontrasttoIBDLPL-
T cells, APN activatesSTAT3 inonlyanti-CD3-stimulated LPL-
Tincontrols.APNmayexertitsstimulatoryeffectsbyactivating
IgG control
 of UC
20x 40x 20x 40x
n i t p e L APN
Control
Active UC
Active CD
with 
Pretreated
recombinant 
APN or 
leptin in UC
Figure 3 Adiponectin and leptin presence in control and inﬂammatory bowel disease (IBD) mucosa. Representative immunohistochemistry for adiponectin (APN) and
leptin in the colonic mucosa of control and active IBD. CD, Crohn’s disease; UC, ulcerative colitis.
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41 Our studies are the ﬁrst
demonstration of such activities in LPL-T.
SOCS3 expression is implicated in inhibiting STAT3
activation. SOCS3 expression by LPL-T was not altered in
control mucosa in the presence of anti-CD3, leptin, or APN.
However, its expression is reduced in anti-CD3 and leptin or
APN-stimulated LPL-T of UC and sharply diminished in CD.
Our data suggest that STAT3 is inhibited by SOCS3 in control
mucosa, but it is constantly activated in the LPL-T of IBD
patients due to the low expression of SOCS3, indicating that
anti-CD3-stimulated LPL-T of IBD patients are more sensitive
to leptin and APN than those of controls. These ﬁndings
support the notion that activated LPL-T, in the presence of
APN or leptin, evades apoptosis. The low rates of LPL-T
apoptosis could be due to STAT3 activation, because
activated STAT3 is critical for T-cell proliferation and
apoptosis resistance.
42 The resistance to apoptosis could
be because of the high ratio of anti-apoptotic protein
expression to pro-apoptotic protein expression,
43 which is
one of the immunological manifestations in the LPL-T of
patients with active IBD. Moreover, IL-10 exerts its anti-
inﬂammatory effect in the presence of SOCS3 suppression
caused by leptin and APN, suggesting that IL-10 may activate
SOCS3orthatitsbioactivityisnotaffectedbythesuppression
of SOCS3.
44
Furthermore, previous studies have reported that HMW
APN may be the active form of APN, as changes in serum
HMW APN, but not total APN levels, have been observed
following treatment with thiazolidinediones, with an asso-
ciated improvement in hepatic insulin sensitivity.
45 On the
other hand, globular APN activates nuclear factor kappa B in
vascular endothelial cells,
46 suggesting that cleavage of APN
at sites of inﬂammation might facilitate the pro-inﬂammation
properties.
47 We found no differences in the ratios of the
molecular weights of APN in the mesenteric fat of control and
IBD subjects, and HMW is the active form of APN as well asof
60
50
40
%
 
L
P
L
-
T
 
a
p
o
p
t
o
s
i
s
30
20
10
0
70
†
† †
†
**
*
** ** ** ** **
*
control LPL-T UC LPL-T *
**
** **
† † CD LPL-T
U
n
t
r
e
a
t
e
d
A
n
t
i
-
C
D
3
A
n
t
i
-
C
D
3
 
+
 
l
e
p
t
i
n
A
n
t
i
-
C
D
3
 
+
 
A
P
N
A
n
t
i
-
C
D
3
 
+
 
A
D
P
A
P
N
 
+
 
W
P
1
0
6
6
e
p
t
i
n
 
+
 
W
P
1
0
6
6
16
14
12
10
8
6
4
18
0
2
16
14
12
10
8
6
4
18
0
2
U
n
t
r
e
a
t
e
d
A
n
t
i
-
C
D
3
n
t
i
-
C
D
3
 
+
 
l
e
p
t
i
n
A
n
t
i
-
C
D
3
 
+
 
A
P
N
A
n
t
i
-
C
D
3
 
+
 
A
D
P
A
P
N
 
+
 
W
P
1
0
6
6
e
p
t
i
n
 
+
 
W
P
1
0
6
6
U
n
t
r
e
a
t
e
d
A
n
t
i
-
C
D
3
n
t
i
-
C
D
3
 
+
 
l
e
p
t
i
n
n
t
i
-
C
D
3
 
+
 
A
P
N
n
t
i
-
C
D
3
 
+
 
A
D
P
P
N
 
+
 
W
P
1
0
6
6
p
t
i
n
 
+
 
W
P
1
0
6
6
A
n
t
i
-
C
D
3
 
+
 
A
n
t
i
-
C
D
3
 
+
 
l
A
n
A
n
t
i
-
C
D
3
 
+
 
A
n
t
i
-
C
D
3
 
+
 
l
e
A
n
A
n
A
n
A
n
t
i
-
C
D
3
 
+
 
A
A
n
t
i
-
C
D
3
 
+
 
l
e
Figure 4 Effect of leptin, adiponectin (APN), and adipocyte-derived product (ADP), in the presence of CD3 monoclonal antibody stimulation and signal transducer and
activatoroftranscription3(STAT3)inhibitor,onlaminapropriaTlymphocyte(LPL-T)apoptosis.LPL-Twereisolatedfromcontrolandactiveinﬂammatoryboweldisease(IBD)
mucosa. LPL-T were incubated overnight with leptin (20ng/ml), APN (2mg/ml), or ADP (4mg/ml) in a 96-well plate pre-coated with anti-CD3 (2mg/ml) and STAT3 inhibitor
WP1066 (3mmol/l). LPL-T apoptosis was detected by Annexin-V and propidium iodide using ﬂow cytometry. *Po0.05 vs. untreated LPL-T. **Po0.05 vs. LPL-T treated with
anti-CD3,
wPo0.05 vs. LPL-T treated with anti-CD3 þ leptin or APN (n¼12 per group).
Table 3 Mucosal levels of leptin and APN and the effect of different protein concentrations of MDP on LPL-T apoptosis
Mucosal area Local leptin level
(ng per mg protein supernatant)
Local APN level
(pg per mg protein supernatant)
% LPL-T apoptosis after
mAb CD3 and MDP stimulation
2±0.2mm
2 mucosa (38±1.3mg weight)
C 2.21±0.1 3.1±0.8 55.7±4.6
UC 32.8.3±2.7 41.2±0.23 13.5±1.1
CD 39.8.1±2.8 44.9.1±0.28 16.5±1.3
1±0.15cm
2 mucosa (200±2.4mg weight)
C 12.2±0.9 17.3±1.3 31.6±3.9
a
UC 190±7.9 223±7.3 7.8±0.8
a
CD 220±8.5 242±10.6 11.3±1.8
a
APN, adiponectin; C, control; CD, Crohn’s disease; mAb, monoclonal antibody; LPL-T, lamina propria T lymphocytes; MDP, mucosal-derived product; UC, ulcerative
colitis.
Note: Data represent the average of leptin and APN levels in two different mucosal sizes and weights obtained from control and active IBD. Values are
average±standard error; n¼12.
aPo0.05 versus % LPL-T apoptosis stimulated with low protein levels of respective MDP (120mg/ml).
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Clinical and Translational Gastroenterologyglobular APN, both of which have pro-inﬂammatory function
25
that may lead to LPL-T apoptosis resistance.
In conclusion, as summarized in Figure 7, our study
demonstrates that leptin and APN are present in the intestinal
mucosaandareinvolvedintheapoptosisresistanceofLPL-T,
possibly by constant STAT3 phosphorylation and inhibition
of SOCS3 expression. Anti-CD3-stimulated LPL-T from IBD
mucosa are more sensitive to APN and leptin to produce
cytokines and evade apoptosis than those from control
mucosa. Local neutralization of leptin and APN that inhibits
STAT3 activation in LPL-T may be a novel therapeutic target
for IBD treatment.
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Figure 6 Signal transducer and activator of transcription 3 (STAT3), p-STAT3, and Suppressor of Cytokine Signaling 3 (SOCS3) expression by lamina propria T
lymphocytes (LPL-T) treated with different stimuli in control and inﬂammatory bowel disease (IBD) mucosa. (a) LPL-T were incubated for 1h with leptin (20ng/ml) or
adiponectin (APN, 2mg/ml) in a 96-well plate pre-coated with anti-CD3 (2mg/ml). STAT3 and p-STAT3 expression was determined by enzyme-linked immunosorbent assay.
*Po0.05 vs. untreated LPL-T in IBD. **Po0.05 vs. anti-CD3-treated LPL-T.
wPo0.05 for p-STAT3 levels in IBD vs. control LPL-T of the respective treatment (n¼12 per
group).(b)Quantitativereversetranscriptase-polymerasechainreaction(RT-PCR)forSOCS3expressionbyLPL-T.Usingthesamedosagesofleptin,APN,andanti-CD3as
previously described, LPL-T were incubated for 1h with leptin or APN in a 96-well plate pre-incubated with anti-CD3. SOCS3 expression was determined by quantitative RT-
PCR. *Po0.05 vs. levels of anti-CD3 treated LPL-T.
wPo0.05 vs. levels of untreated LPL-T (n¼12 per group).
Figure 7 A proposed model for the role of adipokines in inﬂammatory bowel
disease (IBD). Interleukin (IL)-6 and adiponectin (APN) production by adipocytes is
increased near active IBD compared with normal mucosa. Anti-CD3-stimulated
lamina propria T lymphocytes (LPL-T) of active IBD, in the presence of leptin or
APN, activate signal transducer and activator of transcription 3 (STAT3) and induce
IL-6 production, which maintains STAT3 activation. In contrast, anti-CD3-activated
LPL-T of normal mucosa do not induce IL-6 production, in the presence of leptin or
APN, but activate STAT3, where its activity is blunted by Suppressor of Cytokine
Signaling 3 (SOCS3) expression leading to STAT3 inhibition. Apoptosis resistance
occurred in the LPL-T of IBD patients due to continuing STAT3 activity in the
absence of SOCS3, wherein apoptosis occurred in normal mucosa due to the
inhibitory effect of SOCS3 on STAT3 in LPL-T.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
| Cytokines, especially produced by mesenteric
adipocytes, have a key role in the longevity and
over-reactivity of lamina propria T lymphocytes
(LPL-T) in inﬂammatory bowel disease (IBD).
| Creeping fat surrounding Crohn’s disease (CD)
lesions is associated with tumor necrosis factor-alpha,
leptin, and adiponectin (APN) and correlates with
the severity of intestinal inﬂammation and tissue
injury, suggesting an important role for adipose tissue
in the intestinal inﬂammatory process in CD.
| Leptin directly regulates production of several
cytokines, particularly from T cells. Leptin increases
interleukin (IL)-2 and interferon-g production,
while decreasing IL-4 levels. Therefore, leptin may
have an important role in the regulation of the T-helper
1/T-helper 2 balance, which appears to be critical
in the pathogenesis of IBD.
| The role of APN in the inﬂammatory process of
IBD is controversial.
WHAT IS NEW HERE
| The leptin, APN, and IL-6 levels produced
spontaneously by adipocytes near active IBD are
higher than those produced by adipocytes from
inactive segments of the intestine of IBD patients.
| Immune cell inﬁltration in the adipose tissue (AT) near
active CD is signiﬁcantly increased; however, it is not
altered in AT near active ulcerative colitis, indicating the
important role of fat wrapping in CD pathogenesis.
| Both leptin and APN maintain the pro-inﬂammatory
state and increase apoptosis resistance in the
LPL-T of IBD patients through the upregulation
of p-signal transducer and activator of transcription 3,
Bcl-2, and Bcl-xL and inhibition of Suppressor of
Cytokine Signaling 3 expression.
| The local neutralization of leptin and APN may be a
novel therapeutic target for IBD treatment.
1. Bu P, Keshavarzian A, Stone DD et al. Apoptosis: one of the mechanisms that
maintains unresponsiveness of the intestinal mucosal immune system. J Immunol 2001;
166: 6399–6403.
2. Qiao L, Golling M, Autschbach F et al. T cell receptor repertoire and mitotic responses of
lamina propria T lymphocytes in inﬂammatory bowel disease. Clin Exp Immunol 1994; 97:
303–308.
3. Autschbach F, Schurmann G, Qiao L et al. Cytokine messenger RNA expression and
proliferation status of intestinal mononuclear cells in noninﬂamed gut and Crohn’s disease.
Virchows Arch 1995; 426: 51–60.
4. Liu Z, Geboes K, Colpaert S et al. IL-15 is highly expressed in inﬂammatory bowel disease
and regulates local T cell-dependent cytokine production. J Immunol 2000; 164:
3608–3615.
5. Blain A, Cattan S, Beaugerie L et al. Crohn’s disease clinical course and severity in obese
patients. Clin Nutr 2002; 21: 51–57.
6. Sitaraman S, Liu X, Charrier L et al. Colonic leptin: source of a novel proinﬂammatory
cytokine involved in IBD. Faseb J 2004; 18: 696–698.
7. Desreumaux P, Ernst O, Geboes K et al. Inﬂammatory alterations in mesenteric adipose
tissue in Crohn’s disease. Gastroenterology 1999; 117: 73–81.
8. Sheehan AL, Warren BF, Gear MW et al. Fat-wrapping in Crohn’s disease: pathological
basis and relevance to surgical practice. Br J Surg 1992; 79: 955–958.
9. Borley NR, Mortensen NJ, Jewell DP et al. The relationship between inﬂammatory and
serosal connective tissue changes in ileal Crohn’s disease: evidence for a possible
causative link. J Pathol 2000; 190: 196–202.
10. Barbier M, Vidal H, Desreumaux P et al. Overexpression of leptin mRNA in mesenteric
adipose tissue in inﬂammatory bowel diseases. Gastroenterol Clin Biol 2003; 27:
987–991.
11. Yamamoto K, Kiyohara T, Murayama Y et al. Production of adiponectin, an
anti-inﬂammatory protein, in mesenteric adipose tissue in Crohn’s disease. Gut 2005;
54: 789–796.
12. Lord GM, Matarese G, Howard JK et al. Leptin modulates the T-cell immune response and
reverses starvation-induced immunosuppression. Nature 1998; 394: 897–901.
13. Fantuzzi G. Adipose tissue, adipokines, and inﬂammation. J Allergy Clin Immunol 2005;
115: 911–919; quiz 920.
14. Fayad R, Pini M, Sennello JA et al. Adiponectin deﬁciency protects mice from chemically
induced colonic inﬂammation. Gastroenterology 2007; 132: 601–614.
15. Ehling A, Schafﬂer A, Herfarth H et al. The potential of adiponectin in driving arthritis.
J Immunol 2006; 176: 4468–4478.
16. Ogunwobi OO, Beales IL. Adiponectin stimulates proliferation and cytokine secretion in
colonic epithelial cells. Regul Pept 2006; 134: 105–113.
17. LovatoP,Brender C,Agnholt Jetal.ConstitutiveSTAT3activation inintestinal Tcellsfrom
patients with Crohn’s disease. J Biol Chem 2003; 278: 16777–16781.
18. Liao W, Yu C, Wen J et al. Adiponectin Induces Interleukin-6 Production and
Activates STAT3 in Adult Mouse Cardiac Fibroblasts. Biol Cell 2008; 101:
263–272.
19. Akira S. IL-6-regulated transcription factors. Int J Biochem Cell Biol 1997; 29:
1401–1418.
20. Miyazaki T, Bub JD, Uzuki M et al. Adiponectin activates c-Jun NH(2)-terminal kinase and
inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun
2005; 333: 79–87.
21. Riley JK, Takeda K, Akira S et al. Interleukin-10 receptor signaling through the JAK-STAT
pathway.Requirementfortwodistinctreceptor-derivedsignalsforanti-inﬂammatoryaction.
J Biol Chem 1999; 274: 16513–16521.
22. Atreya R, Mudter J, Finotto S et al. Blockade of interleukin 6 trans signaling suppresses T-
cell resistance against apoptosis in chronic intestinal inﬂammation: evidence in crohn
disease and experimental colitis in vivo. Nat Med 2000; 6: 583–588.
23. Catlett-Falcone R, Landowski TH, Oshiro MM et al. Constitutive activation of Stat3
signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;
10: 105–115.
24. Fayad R, Brand MI, Stone D et al. Apoptosis resistance in ulcerative colitis: high
expression of decoy receptors by lamina propria T cells. Eur J Immunol 2006; 36:
2215–2222.
25. Haugen F, Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and
globular adiponectin. Endocrinology 2007; 148: 5478–5486.
26. NeumeierM,WeigertJ,SchafﬂerAetal.Differenteffectsofadiponectinisoforms inhuman
monocytic cells. J Leukoc Biol 2006; 79: 803–808.
27. Schafﬂer A, Furst A, Buchler C et al. Secretion of RANTES (CCL5) and interleukin-10 from
mesenteric adipose tissue and from creeping fat in Crohn’s disease: regulation by steroid
treatment. J Gastroenterol Hepatol 2006; 21: 1412–1418.
28. Hue S, Ahern P, Buonocore S et al. Interleukin-23 drives innate and T cell-mediated
intestinal inﬂammation. J Exp Med 2006; 203: 2473–2483.
29. SaadMF,DamaniS,GingerichRLetal.Sexualdimorphisminplasmaleptinconcentration.
J Clin Endocrinol Metab 1997; 82: 579–584.
30. Rovin BH, Song H. Chemokine induction by the adipocyte-derived cytokine adiponectin.
Clin Immunol 2006; 120: 99–105.
31. Hemmrich K, Thomas GP, Abberton KM et al. Monocyte chemoattractant protein-1 and
nitric oxide promote adipogenesis in a model that mimics obesity. Obesity (Silver Spring)
2007; 15: 2951–2957.
32. Sobhani I, Buyse M, Goiot H et al. Vagal stimulation rapidly increases leptin secretion in
human stomach. Gastroenterology 2002; 122: 259–263.
33. Doering J, Begue B, Lentze MJ et al. Induction of T lymphocyte apoptosis by
sulphasalazine in patients with Crohn’s disease. Gut 2004; 53: 1632–1638.
34. Itoh J, de La Motte C, Strong SA et al. Decreased Bax expression by mucosal T cells
favours resistance to apoptosis in Crohn’s disease. Gut 2001; 49: 35–41.
35. Fujita Y, Murakami M, Ogawa Y et al. Leptin inhibits stress-induced apoptosis of T
lymphocytes. Clin Exp Immunol 2002; 128: 21–26.
36. Brakenhielm E, Veitonmaki N, Cao R et al. Adiponectin-induced antiangiogenesis and
antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci
USA 2004; 101: 2476–2481.
37. Rakatzi I, Mueller H, Ritzeler O et al. Adiponectin counteracts cytokine- and
fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 2004;
47: 249–258.
Adipokines and IBD
Ponemone et al.
11
Clinical and Translational Gastroenterology38. Lu Y, Fukuyama S, Yoshida R et al. Loss of SOCS3 gene expression converts
STAT3 function from anti-apoptotic to pro-apoptotic. J Biol Chem 2006; 281: 36683–
36690.
39. Coll ML, Rosen K, Ladeda V et al. Increased Bcl-xL expression mediates v-Src-induced
resistance to anoikis in intestinal epithelial cells. Oncogene 2002; 21: 2908–2913.
40. Lappas M, Permezel M, Rice GE. Leptin and adiponectin stimulate the release
of proinﬂammatory cytokines and prostaglandins from human placenta and maternal
adipose tissue via nuclear factor-kappaB, peroxisomal proliferator-activated
receptor-gamma and extracellularly regulated kinase 1/2. Endocrinology 2005; 146:
3334–3342.
41. Alberti L, Gilardini L, Girola A et al. Adiponectin receptors gene expression in lymphocytes
of obese and anorexic patients. Diabetes Obes Metab 2007; 9: 344–349.
42. Shirogane T, Fukada T, Muller JM et al. Synergistic roles for Pim-1 and c-Myc in STAT3-
mediated cell cycle progression and antiapoptosis. Immunity 1999; 11: 709–719.
43. InaK, Itoh J, Fukushima K etal. Resistance ofCrohn’s disease T cellstomultiple apoptotic
signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 1999; 163:
1081–1090.
44. Croker BA, Krebs DL, Zhang JG et al. SOCS3 negatively regulates IL-6 signaling in vivo.
Nat Immunol 2003; 4: 540–545.
45. Pajvani UB, Hawkins M, Combs TP et al. Complex distribution, not absolute amount of
adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity.
J Biol Chem 2004; 279: 12152–12162.
46. Tomizawa A, Hattori Y, Kasai K et al. Adiponectin induces NF-kappaB activationthat leads
to suppression of cytokine-induced NF-kappaB activation in vascular endothelial cells:
globular adiponectin vs. high molecular weight adiponectin. Diab Vasc Dis Res 2008; 5:
123–127.
47. Hattori Y, Hattori S, Kasai K. Globular adiponectin activates nuclear factor-kappaB in
vascular endothelial cells, which in turn induces expression of proinﬂammatory and
adhesion molecule genes. Diabetes Care 2006; 29: 139–141.
Clinical and Translational Gastroenterology is an open-
access journal published by Nature Publishing Group.
This work is licensed under the Creative Commons Attribution-
Noncommercial-No Derivative Works 3.0 Unported License. To view a
copy of this license, visit http://creativecommons.org/licenses/by-nc-
nd/3.0/
SupplementaryInformationaccompaniesthispaperontheClinicalandTranslationalGastroenterologywebsite(http://www.nature.com/ctg)
Adipokines and IBD
Ponemone et al.
12
Clinical and Translational Gastroenterology